Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vivesto ABOASMY 26 EV-to-EBITDA is 0.56 as of Jul. 26, 2026. GuruFocus rates OASMY with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 742 Drug Manufacturers companies, Vivesto AB ranks worse than 134770.75% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vivesto AB's enterprise value is $-1.86 Mil.
Vivesto AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-3.32 Mil. Therefore, Vivesto AB's EV-to-EBITDA for today is 0.56.
The historical rank and industry rank for Vivesto AB's EV-to-EBITDA or its related term are showing as below:
OASMY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -246.25 Med: -4.95 Max: 307.68
Current: -3.5
During the past 13 years, the highest EV-to-EBITDA of Vivesto AB was 307.68. The lowest was -246.25. And the median was -4.95.
OASMY's EV-to-EBITDA is ranked worse than 100% of 742
companies
in the Drug Manufacturers industry
Industry Median: 12.98
vs OASMY: -3.50
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Vivesto AB (OTCPK:OASMY) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vivesto AB's share price for today is $0.0001.
Vivesto AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.014.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Vivesto AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vivesto AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivesto AB EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vivesto AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vivesto AB's EV-to-EBITDA falls into.
Vivesto AB's current Enterprise Value is $-1.86 Mil.
Vivesto AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.32 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vivesto AB (OASMY) has a EV-to-EBITDA of 0.56 as of Jul. 26, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vivesto AB. According to the industry distribution chart, Vivesto AB ranks #999999 out of 742 companies in the Drug Manufacturers industry.
Is Vivesto AB's EV-to-EBITDA too high?
Vivesto AB's current EV-to-EBITDA is 0.56. The Drug Manufacturers industry median EV-to-EBITDA is 12.98. Vivesto AB's value of 0.56 is 95.7% below this industry median. Based on the distribution chart, Vivesto AB ranks #999999 out of 742 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vivesto AB has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Vivesto AB's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vivesto AB ranks #999999 out of 742 companies for EV-to-EBITDA. This places Vivesto AB in the lower half of its industry. The industry median EV-to-EBITDA is 12.98. Vivesto AB's value of 0.56 is 95.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.98, based on 742 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vivesto AB's current EV-to-EBITDA of 0.56 is 95.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vivesto AB. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivesto AB's current EV-to-EBITDA is 0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivesto AB stock overvalued right now?
Vivesto AB (OASMY) has a current EV-to-EBITDA of 0.56. The current EV-to-EBITDA is 0.56 and 95.7% below the Drug Manufacturers industry median of 12.98. Vivesto AB's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Vivesto AB (OASMY), the current EV-to-EBITDA is 0.56 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.
26GF Score
Get the complete analysis for OASMY
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OASMY has been successfully added to your 
